We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+2.09%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.09B
AUM Growth
-$133M
Cap. Flow
+$26.4M
Cap. Flow %
0.52%
Top 10 Hldgs %
35.29%
Holding
140
New
25
Increased
26
Reduced
29
Closed
16

Top Buys

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$161M
2
BIIB icon
Biogen
BIIB
+$68.3M
3
BAX icon
Baxter International
BAX
+$66.2M
4
LLY icon
Eli Lilly
LLY
+$62.7M
5
APLS
Apellis Pharmaceuticals
APLS
+$52.5M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$117M
2
PFE icon
Pfizer
PFE
+$71.4M
3
UNH icon
UnitedHealth
UNH
+$50.4M
4
NTRA icon
Natera
NTRA
+$46.7M
5
ETNB
89bio
ETNB
+$46.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.7%
2 Industrials 0.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVA
1
DELISTED
Sinovac Biotech, Ltd
SVA
$340M 6.67%
2,718,735
– –
ELVN icon
2
Enliven Therapeutics
ELVN
$3.84B
$197M 3.87%
8,996,213
+7,899,571
+720% +$161M
BSX icon
3
Boston Scientific
BSX
$68.5B
$190M 3.72%
3,790,000
-108,200
-3% -$5.1M
HUM icon
4
Humana
HUM
$46.7B
$169M 3.32%
348,700
– –
BMY icon
5
Bristol-Myers Squibb
BMY
$130B
$162M 3.18%
2,340,000
-244,900
-9% -$17.3M
ISRG icon
6
Intuitive Surgical
ISRG
$130B
$159M 3.11%
620,500
– –
BMRN icon
7
BioMarin Pharmaceuticals
BMRN
$12B
$157M 3.08%
1,615,210
– –
THRX
8
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$153M 3%
17,233,668
– –
BIIB icon
9
Biogen
BIIB
$30.4B
$140M 2.76%
505,000
+246,800
+96% +$68.3M
UNH icon
10
UnitedHealth
UNH
$389B
$130M 2.56%
276,000
-104,500
-27% -$50.4M
SRPT icon
11
Sarepta Therapeutics
SRPT
$1.63B
$119M 2.34%
865,100
-107,200
-11% -$13.9M
SWTX
12
DELISTED
SpringWorks Therapeutics
SWTX
$116M 2.27%
4,498,900
-751,100
-14% -$22M
SYK icon
13
Stryker
SYK
$133B
$105M 2.06%
367,600
-113,400
-24% -$30.1M
EWTX icon
14
Edgewise Therapeutics
EWTX
$4.34B
$97.2M 1.91%
14,567,176
– –
EVH icon
15
Evolent Health
EVH
$421M
$94M 1.84%
2,895,632
+70,800
+3% +$2.24M
TERN
16
DELISTED
Terns Pharmaceuticals
TERN
$90.2M 1.77%
7,619,135
– –
VRNA
17
DELISTED
Verona Pharma
VRNA
$85.6M 1.68%
4,260,691
-311,598
-7% -$6.73M
TMO icon
18
Thermo Fisher Scientific
TMO
$214B
$85.2M 1.67%
147,800
-54,400
-27% -$30.7M
IONS icon
19
Ionis Pharmaceuticals
IONS
$9.14B
$75.9M 1.49%
2,124,500
+130,900
+7% +$4.92M
CMPX icon
20
Compass Therapeutics
CMPX
$367M
$73.1M 1.44%
22,362,850
– –
THC icon
21
Tenet Healthcare
THC
$22.6B
$72.5M 1.42%
1,220,300
– –
KROS icon
22
Keros Therapeutics
KROS
$199M
$71.7M 1.41%
1,679,417
– –
LLY icon
23
Eli Lilly
LLY
$1.09T
$63.9M 1.25%
+186,000
New +$62.7M
CRNX icon
24
Crinetics Pharmaceuticals
CRNX
$8.88B
$63.4M 1.25%
3,950,796
+753,920
+24% +$14M
BAX icon
25
Baxter International
BAX
$12.6B
$63.4M 1.24%
+1,562,000
New +$66.2M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2023 Portfolio in Review

As of Q1 2023, OrbiMed held 140 positions worth $5.09B, down 2.6% from $5.23B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed's Q1 2023 filing shows 25 new, 26 increased, 29 reduced and 16 closed positions. Its largest new stake was Baxter International: 1,562,000 shares worth $63.4M. The largest sale was Seagen Inc. Common Stock, an estimated $117M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Industrials.

  • OrbiMed's largest Q1 2023 buy was Baxter International: 1,562,000 shares worth $63.4M.
  • OrbiMed added most to Enliven Therapeutics in Q1 2023, an estimated $161M increase.
  • OrbiMed's biggest Q1 2023 reduction was UnitedHealth, cutting an estimated $50.4M.
  • OrbiMed fully exited Seagen Inc. Common Stock in Q1 2023, selling an estimated $117M.
  • OrbiMed's ten largest holdings make up 35% of its $5.09B portfolio in Q1 2023.
  • OrbiMed opened 25 new positions and closed 16 in Q1 2023.
  • OrbiMed's portfolio value fell 2.6% quarter-over-quarter to $5.09B.

Based on OrbiMed's 13F filing for Q1 2023, filed 15 May 2023.